

## **Supplemental Information**

### **G<sub>s</sub>α deficiency in the dorsomedial hypothalamus underlies obesity associated with G<sub>s</sub>α mutations**

Min Chen<sup>1\*</sup>, Yogendra B. Shrestha<sup>1\*</sup>, Brandon Podyma<sup>1,3</sup>, Zhenzhong Cui<sup>2</sup>, Benedetta Naglieri<sup>1</sup>, Hui Sun<sup>1</sup>, Thuy Ho<sup>1,3</sup>, Eric A. Wilson<sup>1</sup>, Yong-Qi Li<sup>1</sup>, Oksana Gavrilova<sup>2</sup>, and Lee S. Weinstein<sup>1</sup>

<sup>1</sup>Metabolic Diseases Branch and <sup>2</sup>Mouse Metabolism Core Laboratory, National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA

<sup>3</sup>Present address: University of Virginia School of Medicine, Virginia, USA

\*Co-first author

## Supplemental Methods


*Chronic cold adaptation.* For chronic cold adaptation, mice were kept in individual cages with bedding within a climate control chamber (Memmert 750 LIFE Chamber) and kept in 30°C for 3 d to minimize SNS activity, and temperature was lowered to 22°C and then decreased by 2°C/d until 6°C was reached. At that point the mice were housed at 6°C for a further 7 d. Mice had full access to food and water throughout and showed no obvious untoward effects during adaptation.

*Immunohistochemistry.* Fat pads were fixed with 10% formalin. Tissue sections (5- $\mu$ m thick for BAT and 8- $\mu$ m thick for WAT) were treated in 10 mM sodium citrate, 0.05% Tween 20 at 85°C for 20 min, and then in 3% hydrogen peroxide for 10 min. After blocking in 5% BSA for 20 min, the sections were incubated with anti-F4/80 antibody (Biorad, catalog #MCA497; 1:100 dilution) or anti-UCP1 antibody (Abcam, catalog #Ab10983; 1:1000 dilution) at 4°C overnight, and then incubated with biotinylated goat anti-rabbit IgG secondary antibody (Agilent DAKO, catalog #E043201-6; 1:500 dilution) at room temperature for 1 h. The F4/80 or UCP1 signals were detected using streptavidin-horse radish peroxidase (Vector Laboratories), and visualized with diaminobenzidine tetrahydrochloride (Sigma). The sections were counterstained with hematoxylin.

*Immunoblotting.* BAT samples were homogenized in 1 x RIPA buffer (Cell Signaling) supplemented with protease inhibitor cocktail tablet. Lysates were centrifuged at 13,000 rpm for 10 min at 4°C, and the supernatants were used for immunoblotting. Protein extracts (30  $\mu$ g) were separated on NovexN uPAGE 4-12% Bis-Tris gels (Life Technologies) and transferred using an iBlot 2 Dry Blotting System (Life Technologies), which was sequentially incubated with anti-UCP1 (Abcam, catalog #Ab10983) and anti-


$\alpha$ -tubulin antibodies (Calbiochem, catalog #CP06). Bands were quantified using the ChemiDOC MP imaging system (Biorad) and UCP1 protein levels were normalized to  $\alpha$ -tubulin protein levels.

## Supplemental Figure 1




**Supplemental Figure 1. Confirmation of stereotaxic injection position in DMHG sKO mice.** (A) Representative image of AAV-Cre-GFP location indicated with green fluorescence. VMH, ventromedial nucleus of hypothalamus. (B) Body weight of mDMHG sKO and their control littermates at 4-5 mo post-injection separated by mice in which the injection into DMH was confirmed to be correctly targeted either unilaterally (n = 4-6/group) or bilaterally (n = 17-25/group). (C) Body weight of pDMHG sKO mice and their control littermates at 4-5 mo post-injection separated by mice in which the injection into DMH was confirmed to be correctly targeted either unilaterally (n = 2-4/group) or bilaterally (n = 5-10/group). Data are mean  $\pm$  SEM. \*\* $P < 0.01$  vs. controls by Students *t* test.

**Supplemental Figure 2**




**Supplemental Figure 2. Increased inflammation in mDMHGskO white adipose tissue.** Representative immunohistochemical staining for the macrophage marker F4/80 in epididymal (Epi) and inguinal (Ing) WAT from mDMHGskO and pDMHGskO mice and their respective controls (scale bar, 100 μM).

### Supplemental Figure 3




**Supplemental Figure 3. WAT and BAT adaptation to chronic cold exposure.** (A) Rectal temperature in mDMHGSKO and pDMHGSKO mice and their respective controls (n = 3/group) after exposure to gradually declining of ambient temperature down to 6°C and maintaining 6°C for 7 d (temperature during each day indicated on top of graph). (B and C) BAT *Ucp1* gene expression in (B) mDMHGSKO and (C) pDMHGSKO mice and their respective controls after being maintained at room temperature (22°C) or after chronic cold adaptation as outlined in panel A (n = 3/group). (D) H & E stained sections of BAT from control, mDMHGSKO, and pDMHGSKO mice either maintained at 22°C or after chronic cold adaptation to 6°C (scale bar, 100 μm) (E) Immunohistochemistry with an anti-UCP1 antibody of inguinal WAT sections from the same mice as panel D. The data in panels D and E is representative of what was observed in 3 mice per group. Data are mean ± SEM. \*\**P* < 0.05 vs. 22°C by Students *t* test.

Supplemental Figure 4




**Supplemental Figure 4 BAT UCP1 protein response to cold in control and DMH-MC4RKO mice.** (A) Representative immunoblot (one of two experiments) for BAT UCP1 and  $\alpha$ -tubulin protein levels in male control and DMH-MC4RKO mice at room temperature (22°C, RT) and after 6 h at 4°C (Cold). (B) Quantitation of UCP1 protein levels normalized to  $\alpha$ -tubulin (n = 4-5/group) Data are mean  $\pm$  SEM. \* $P$  < 0.05 or \*\* $P$  < 0.01 vs. RT by Student's  $t$  test.

## Supplemental Figure 5



**Supplemental Figure 5. Glucose metabolism in DMH-MC4RKO mice.** (A) Glucose tolerance test (left panel) and areas under curve (AUC, right panel) performed on male DMH-MC4RKO and control mice at 2-2.5 mo post-injection ( $n = 11-13/\text{group}$ ). (B) Insulin tolerance test (left panel) and areas below baseline (ABB, right panel) in the same mice ( $n = 11-14/\text{group}$ ). (C) Glucose tolerance test (left panel) and areas under curve (AUC, right panel) performed on male DMH-MC4RKO and control mice at 2 wk post-injection ( $n = 5-7/\text{group}$ ). (D) Fasting insulin levels in DMH-MC4RKO and control mice at 2 wk post-injection ( $n = 4-5/\text{group}$ ). (E) Body weights of mice studied in panel C. Data are mean  $\pm$  SEM. \* $P < 0.05$  vs. control by Student's  $t$  test.

Supplemental Figure 6



**Supplemental Figure 6. Present model of G proteins involved in MC4R actions.** POMC neurons from the arcuate nucleus project to the PVN and DMH, respectively. Activation of MC4R by release of melanocortins in PVN results in reduced food intake via activation of G<sub>q/11</sub> $\alpha$ , while activation of MC4R in DMH leads to increased energy expenditure and thermogenesis via activation of G<sub>s</sub> $\alpha$ .

## Supplemental Table 1

**Supplemental Table 1. Serum chemistries in fed DMH-MC4RKO and control mice at 2-2.5 mo post-injection**

	<b>DMH-MC4RKO</b>	<b>Control</b>
Glucose (mg/dl)	156 ± 4	212 ± 25
Insulin (ng/ml)	3.9 ± 1.1	11.5 ± 1.4**
Free fatty acids (mM)	0.24 ± 0.03	0.21 ± 0.02
Triglycerides (mg/dl)	98 ± 148	144 ± 20
Cholesterol (mg/dl)	85 ± 5	115 ± 6**
Leptin (ng/ml)	19.4 ± 5.0	83.2 ± 18.7*

Data are mean ± SEM.; \* $P < 0.05$  or \*\* $P < 0.01$  vs. controls;  $n = 7-9$ /group by Students  $t$  test.